Dexcom (DXCM) Net Cash Flow (2010 - 2026)

Dexcom (DXCM) has reported Net Cash Flow for 17 consecutive years, with -$8.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 103.49% year-over-year to -$8.3 million in Q2 2026; TTM through Jun 2026 was -$50.1 million, a 124.61% decrease from a year earlier, with the FY2025 full-year figure at $290.3 million, up 515.04% from the prior year.
• Net Cash Flow was -$8.3 million for Q2 2026 at Dexcom, down from $202.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $677.7 million in Q3 2025 and troughed at -$921.6 million in Q4 2025.
• A 5-year average of $2.8 million and a median of -$6.1 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 2331.78% in 2023 and slumped 23530.77% in 2025, its largest moves.
• Over 5 years, Net Cash Flow stood at -$62.6 million in 2022, then tumbled by 33.23% to -$83.4 million in 2023, then surged by 95.32% to -$3.9 million in 2024, then tumbled by 23530.77% to -$921.6 million in 2025, then surged by 99.1% to -$8.3 million in 2026.
• The last three Net Cash Flow figures came in at -$8.3 million (Q2 2026), $202.1 million (Q1 2026), and -$921.6 million (Q4 2025), per Business Quant data.